CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
News Dec 30, 2013
UBM Live has announced that CPhI Japan is returning for its twelfth year to Tokyo, from the 9th to the 11th April, 2014. The event will once again be co-locating to provide an all-round experience, creating a pivotal meeting-point for all sectors of the pharmaceutical industry.
The full line-up of events includes ICSE Japan, a dedicated outsourcing event designed to connect the pharmaceutical community with contract service providers; P-MEC Japan, delivering innovative pharmaceutical technology, machinery and equipment to a forum of decision makers; BioPh Japan, showcasing the biopharma sector, and a further two events- Pharmatec, providing a pharmaceutical packaging focus and MEDTEC Japan, specializing in medical devices.
Japan is the second largest pharmaceutical market in the world and has been forecast to grow even further at a CAGR of 2.6% until 2016, reaching a total value of US$127.4 billion. The pharma community in the country continues to innovate, particularly in regards to medical devices, with growth facilitated through a reduction in stringent regulatory guidelines. These factors have enabled the Japanese pharma market to open up to foreign investment, meaning that there has never been a better time to attend CPhI Japan and its co-located events.
Last year the event hosted over 14,000 attendees and more than 500 exhibitors, with 2014 predicted to be even bigger and better. A major highlight for this year’s event is again the 150 free seminars covering current industry trends and providing invaluable insights into the dynamic Japanese pharmaceutical industry.
Contributors to the seminars include a wide spectrum of esteemed representatives including the Ministry of Health, Labour & Welfare Japan and the European Federation of Pharmaceutical Industries & Associations Japan (EFPIA Japan).
Furthermore, exhibitors are invited to take part in this year’s presentation series, to educate the industry about their latest products, services, innovations and company news during a 30-minute presentation that will be attended by visitors, press and fellow exhibitors. Online registration to attend the event is now available and is free.
“The Japanese pharmaceutical market is second only to the US, representing one of the strongest areas for those looking to invest. More recently, Japan has seen more amicable regulatory guidelines, which has generated an attractive platform for international investment and our event provides the ultimate setting for both suppliers and buyers to benefit from this dynamic market,” Chris Kilbee, Group Director, CPhI & Pharma.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE